Morningstar

Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference

Provided by ACCESS Newswire

STOCKHOLM, SE / ACCESS Newswire / August 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Pareto Securities 17th Annual Healthcare Conference in Stockholm.

Location: Hotel At Six, Stockholm, Sweden
Format: Presentation and 1×1 meetings
Presentation Date and Time: Wednesday, September 2, 2026, 14:25-14:45 CEST
Participant: Hans Jeppsson, Chief Financial Officer

For more information, please contact:
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Present at the Pareto Securities 17th Annual Healthcare Conference

SOURCE: Vicore Pharma Holding



View the original press release on ACCESS Newswire

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.
Tori Brovet

14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark

Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options.
Russel Kinnel and Ivanna Hampton

4 Stocks to Buy Before They Rise Further

Plus, the member of the triple-digit club reporting earnings this week.
David Sekera, CFA and Susan Dziubinski

The Top Funds for a Simpler Retirement Portfolio

For retirement savers and retirees, Christine Benz highlights all-in-one funds and core funds that can serve as building blocks for a streamlined portfolio.
Christine Benz

The 10 Best Dividend Stocks

These are the top dividend-paying stocks to buy today.
Susan Dziubinski

Sponsor Center